Patrick Yeramian
Corporate Officer/Principal chez Dlx Therapeutics L L C
Fortune : 583 918 $ au 31/03/2024
Profil
Patrick D.
Yeramian is currently the General Manager at Dlx Therapeutics L L C.
Previously, he worked as a Medical Director at Pfizer Inc., Marker Therapeutics, Inc., Vaccine & Gene Therapy Institute of Florida Corp., Kantum Pharma, Inc., and Tapimmune, Inc. He also served as the Director-Clinical Research at G.D.
Searle LLC and as the Chief Medical Officer at Viragen, Inc. and BioVie, Inc. Additionally, he is currently the Chief Medical Officer & Global Head-Clinical R&D at Amylyx Pharmaceuticals, Inc. Dr. Yeramian holds a graduate degree from Université de Paris XI Paris Sud, a doctorate from Universite Paris Est.
Creteil Val De Marne, and an MBA from Rutgers Business School.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 09/01/2024 | 205 605 ( 0,30% ) | 583 918 $ | 31/03/2024 |
Postes actifs de Patrick Yeramian
| Sociétés | Poste | Début |
|---|---|---|
| Dlx Therapeutics L L C | Corporate Officer/Principal | 01/01/2018 |
Anciens postes connus de Patrick Yeramian
| Sociétés | Poste | Fin |
|---|---|---|
| AMYLYX PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 28/11/2023 |
| BIOVIE INC. | Chief Tech/Sci/R&D Officer | 01/11/2021 |
Kantum Pharma, Inc.
 Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Chief Tech/Sci/R&D Officer | 01/03/2019 |
| MARKER THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 01/01/2017 |
| Tapimmune, Inc. | Chief Tech/Sci/R&D Officer | 01/01/2017 |
Formation de Patrick Yeramian
| Universite Paris Est Creteil Val De Marne | Doctorate Degree |
| Rutgers Business School | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| PFIZER, INC. | Health Technology |
| MARKER THERAPEUTICS, INC. | Health Technology |
| BIOVIE INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Viragen, Inc.
 Viragen, Inc. BiotechnologyHealth Technology Viragen, Inc. is a biotechnology company specializing in the research, development and commercialization of natural and recombinant protein-based drugs designed to treat a broad range of viral and malignant diseases. These protein-based drugs include natural human alpha interferon and monoclonal antibodies. Viragen's strategy also includes the development of Avian Transgenic Technology as a biomanufacturing platform for the large-scale, cost-effective production of therapeutic proteins. The firm is located in Plantation, FL. | Health Technology |
| Université de Paris XI Paris Sud | Consumer Services |
| G.D. Searle LLC | |
Vaccine & Gene Therapy Institute of Florida Corp.
 Vaccine & Gene Therapy Institute of Florida Corp. Miscellaneous Commercial ServicesCommercial Services Vaccine & Gene Therapy Institute of Florida Corp. provides research services. The non-profit company is based in Port Saint Lucie, FL. | Commercial Services |
| Amylyx Pharmaceuticals, Inc. | |
Kantum Pharma, Inc.
Kantum Pharma, Inc. Miscellaneous Commercial ServicesCommercial Services Kantum Pharma, Inc. operates as a biopharmaceutical company. It focuses on developing therapies for the prevention and treatment of damaging inflammation. The company was founded by Sylvie Breton and is headquartered in Concord, NH. | Commercial Services |
| Dlx Therapeutics L L C | |
| Tapimmune, Inc. |
